A Phase 1/2A Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)

Trial Profile

A Phase 1/2A Single Center Trial of Gene Transfer for Recessive Dystrophic Epidermolysis Bullosa (RDEB) Using the Drug LZRSE-Col7A1 Engineered Autologous Epidermal Sheets (LEAES)

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 06 Jun 2018

At a glance

  • Drugs EB 101 (Primary)
  • Indications Epidermolysis bullosa
  • Focus Proof of concept; Therapeutic Use
  • Most Recent Events

    • 06 Jun 2018 According to an Abeona therapeutics media release, data from this study will be presented at the Jefferies 2018 Global Healthcare Conference.
    • 17 May 2018 Primary endpoint Percentage surface area of wound healing has been met, according to the Abeona Therapeutics media release.
    • 17 May 2018 Results presented in the Abeona Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top